Other Names
Diplacus kelloggiiEunanus kelloggiiKellogg's monkeyflowerMimulus kelloggii
Kelloggii's monkey-flower, known in commerce as "Kelloggii's Monkey-flower," carries the current accepted botanical name Erythranthe kelloggii and was formerly classified as Mimulus kelloggii. A further synonym in some taxonomic databases is Diplacus kelloggii. The name change reflects a major restructuring of the genus Mimulus that took place in 2012. In that restructuring by Barker et al., based largely upon DNA evidence, seven species were left in Mimulus as strictly defined; Erythranthe was greatly enlarged to include 111 species, based upon axile placentation and long pedicels, while 46 species were placed into Diplacus.
Historically, most monkey-flowers were classified under the genus Mimulus; however, recent taxonomic revisions have divided the genus, leading to the reclassification of many species into the genera Erythranthe and Diplacus, based on molecular phylogenetic studies. This split, primarily affecting western North American species, reflects a more accurate understanding of evolutionary relationships. Within this framework, Erythranthe includes herbaceous species, while Diplacus contains shrubby types.
Monkey-flowers β including Erythranthe kelloggii β belong to the lopseed family Phrymaceae, all of which were formerly placed in the single genus Mimulus. The taxonomy of the group was thoroughly revised to better reflect evolutionary relationships, and many species were moved from Mimulus (now 7 species) to Erythranthe (111 species), Diplacus (46 species), and certain smaller genera. Mimulus and its close relatives belong to the order Lamiales. The species epithet kelloggii honors the 19th-century California botanist Albert Kellogg.
The debate over whether to retain the old genus name is ongoing in botanical circles. Taxonomic revision has split the focal species into separate genera, Diplacus and Erythranthe, based on the 2012 Barker et al. work; however, some researchers have elected to retain the use of the name Mimulus for its historic significance and recognizability. For this reason, supplement product labels and older botanical literature may refer to this species interchangeably as Mimulus kelloggii, Erythranthe kelloggii, or Diplacus kelloggii.
Kellogg's monkeyflower is a species of monkeyflower native to the mountains and foothills of northern California and southern Oregon, where it grows in bare, disturbed, and shifting substrates, such as recent rockslides and scree.
It is an annual herb producing a hairy stem reaching maximum heights between 1 and 31 centimeters. The oppositely arranged oval leaves are up to 4 centimeters in length and green in color, sometimes with purple undersides. The narrow, tubular base of each flower is encapsulated in a thick calyx of sepals with uneven lobes. The funnel-shaped flower is up to 4.5 centimeters long, opening into a wide mouth, with two upper lobes wider than the three lower. The flower is reddish-purple in color, darkening in the throat where it is spotted with yellow.
The common name "monkey-flower" is derived from the distinctive face-like appearance of the blossoms. The name "Mimulus" may come either from the Greek mimo, meaning "an ape," because of a resemblance in the markings to the face of a monkey, or from the Latin mimus, meaning "an actor or mimic," because the flower is like the mouthpiece of one of the grinning masks worn by classical actors.
As a supplement ingredient or botanical preparation, Kelloggii's monkey-flower has appeared in the following forms, as noted in available sources:
It is important to note that standardized, commercially manufactured dosage forms (capsules, tablets, tinctures with specified extract ratios) specific to Erythranthe kelloggii are not described in any peer-reviewed literature identified for this article.
The ethnobotanical record for the Phrymaceae monkey-flowers in western North America is primarily associated with more common and widespread species β especially Mimulus guttatus (common monkeyflower / seep monkeyflower, now Erythranthe guttata) β rather than with Erythranthe kelloggii specifically. Specific documentation for Kelloggii's monkey-flower is limited, and most references are general for the genus or closely related species, such as Mimulus guttatus or Mimulus cardinalis.
For the more extensively documented Mimulus guttatus, ethnobotanical records describe several distinct indigenous uses in California and the broader West:
The plant was recognized as astringent, poultice-forming, and vulnerary; a decoction of the leaves and stems was used as a herbal steam bath for chest and back soreness, and a poultice of the crushed leaves was applied to wounds and rope burns.
Historically, monkey-flowers, including Kelloggii's variety, have held a place in indigenous medicinal traditions. Native American tribes, particularly those in California, recognized the plant for its soothing and cleansing properties. Kelloggii's monkey-flower has a history of traditional use among some Indigenous peoples of western North America, particularly in the treatment of minor skin conditions such as scratches and abrasions.
Ethnobotanical records, including those compiled by early 20th-century botanists and anthropologists, indicate that related monkey-flower species were used topically for their perceived soothing and healing properties. However, it must be stated clearly that specific historical documentation regarding Mimulus kelloggii is limited, and most ethnobotanical records focus on the broader genus. No species-specific pre-modern primary ethnobotanical monograph for E. kelloggii was identified in the peer-reviewed literature searches conducted for this article.
The genus Mimulus (broadly defined) has a distinct place in the complementary medicine system developed by British physician Dr. Edward Bach in the 1930s. Bach flower remedies (BFRs) are a widely available, popular form of complementary and alternative medicine developed in the 1930s by Dr. Edward Bach, who devoted his life to the discovery of 38 remedies that correspond to 38 negative emotional states.
Dr. Edward Bach, in the 1930s, identified Mimulus as a key component in his homeopathic system for its purported ability to help alleviate fear and anxiety, especially fears of known origin. Within the Bach system, the essences of particular flowers were prescribed for specific conditions; nervousness was associated with Mimulus. Mimulus fears are characterized as those of every day: fear of public speaking, of the dark, of aggressive dogs, of illness and pain. Phobias can also be Mimulus fears if the cause of the fear β whether spiders, birds, or open spaces β can be named.
It should be noted that the specific Mimulus species used in the original Bach flower remedy system was primarily Mimulus guttatus (common yellow monkeyflower), not Erythranthe kelloggii. The application of Bach-system traditions to Kelloggii's monkey-flower specifically is a more recent extrapolation in the supplement marketplace, not an attribution found in Bach's original writings.
As of the searches conducted for this article, no peer-reviewed phytochemical studies specifically analyzing the chemical composition of Erythranthe kelloggii (syn. Mimulus kelloggii) were identified in PubMed/PMC or other major academic databases. All phytochemical characterization available derives from studies of related Mimulus / Erythranthe species or from the broader genus level.
The genus Mimulus is recognized for containing phytochemicals such as flavonoids and phenolic acids, which have been associated with antioxidant activity in preliminary laboratory studies.
The anthocyanin pigments that give monkey-flowers their characteristic reddish-purple coloration are also of phytochemical interest. Variations in color in the genus Erythranthe largely reflect concentrations of anthocyanins. Research into the genetic control of these pigments has identified relevant transcription factors in closely related species.
Iridoid glycosides are a compound class broadly distributed across the order Lamiales (to which Phrymaceae belongs). Iridoids are a class of active compounds that widely exist in the plant kingdom; with advances in phytochemical research, many compounds with novel structure and outstanding activity have been identified. Iridoid compounds have been confirmed to mainly exist as the prototype and aglycone metabolites by biological transformation, and these metabolites have been shown to have neuroprotective, hepatoprotective, anti-inflammatory, antitumor, hypoglycemic, and hypolipidemic activities. Whether iridoids are present in Erythranthe kelloggii specifically has not been confirmed in any primary study identified here.
Based solely on genus- and family-level data, the following compound classes are plausibly present in Erythranthe kelloggii, though none have been confirmed by species-specific analysis in the peer-reviewed literature reviewed:
No specific compound isolations, quantitative phytochemical analyses, or mechanism-of-action studies specific to Erythranthe kelloggii were identified in the peer-reviewed literature.
Critical caveat: There are currently no large-scale clinical studies on Kelloggii's monkey-flower. Despite these traditional uses, there is little to no scientific research validating the efficacy or safety of Kelloggii's monkey-flower for treating skin abrasions or scratches. Every sub-section below therefore characterizes the evidence honestly as absent, preliminary, or extrapolated from related species or systems.
Traditional claim: Kelloggii's monkey-flower was commonly used in poultices and washes to address minor skin irritations, wounds, and insect bites, with the plant's mucilaginous texture believed to facilitate healing and reduce inflammation.
Scientific evidence: No in vitro, animal, or clinical studies specifically evaluating Erythranthe kelloggii extracts for wound healing were identified. The related species Mimulus guttatus has a documented historical application to wounds β the Shoshoni applied a poultice of crushed leaves to wounds or rope burns β but no laboratory or clinical studies confirming these wound-healing properties were found for that species either.
Evidence strength: None (no experimental studies identified for this species or the broader traditional claim).
Traditional claim: Decoctions of the leaves and flowers were sometimes consumed to ease digestive discomfort and support general wellness. Similarly, related species had comparable uses: the Yavapai used a decoction taken as tea for stomachache.
Scientific evidence: No in vitro, animal, or human clinical trials evaluating gastrointestinal effects of Erythranthe kelloggii or closely related species were identified.
Evidence strength: None (traditional attribution only).
Mechanistic rationale: The genus Mimulus is recognized for containing flavonoids and phenolic acids, which have been associated with antioxidant activity in preliminary laboratory studies; these compounds may support cellular health and help combat oxidative stress.
Scientific evidence: These observations are genus-level generalizations. No antioxidant assays (e.g., DPPH, FRAP, ORAC) using extracts of Erythranthe kelloggii specifically were identified in the literature. No human trials addressing oxidative stress endpoints with this species were identified.
Evidence strength: Highly preliminary β theoretical extrapolation from genus-level phytochemical data only; no species-specific data.
Traditional / ethnopharmacological claim: Within the broader Mimulus Bach flower remedy tradition, Mimulus addresses fears with identifiable causes, such as fear of heights, public speaking, or specific situations. Mimulus is used as a type or personality remedy for those who tend generally to be nervous, timid, and shy.
Scientific evidence: The scientific evidence base for Bach flower remedies as a whole is weak. There is no scientific evidence that any Bach flower remedy produces a medicinal effect, and there is some evidence that the method does not work.
A systematic review published in BMC Complementary and Alternative Medicine (Thaler et al., 2009) examined the available controlled trial evidence. Most of the available evidence regarding the efficacy and safety of BFRs has a high risk of bias. The reviewers concluded that, based on the reported adverse events in six trials, BFRs are probably safe. Few controlled prospective trials of BFRs for psychological problems and pain exist, and analysis of the four controlled trials of BFRs for examination anxiety and ADHD indicated that there is no evidence of benefit compared with a placebo intervention.
One double-blind, placebo-controlled, randomized trial examined a combination of ten Bach flower preparations for test anxiety. The combination included impatiens, mimulus, gentian, chestnut bud, rock rose, larch, cherry plum, white chestnut, scleranthus, and elm; 61 subjects provided informed consent and baseline data, with 32 randomized to receive Bach flower remedies in the first phase and 29 randomized to placebo. Because this trial used a multi-herb combination rather than Mimulus alone, no conclusions about any single flower preparation can be drawn from it.
A study from a homeopathic medical college involving adult patients with generalized anxiety disorder (GAD-7 score >8) found that the most-frequently indicated Bach remedy was Impatiens, followed by Rescue Remedy, Larch, Mimulus, and others. Those taking Bach flowers did improve, but without a placebo control group it is impossible to say whether this was due to a specific action of the remedies or only to positive expectations.
Research specifically focusing on Mimulus extract in clinical settings is sparse, and most available evidence arises from anecdotal reports and observational studies related to Bach flower remedies as a whole.
Evidence strength: Very weak. Controlled trial data for Bach flower remedies as a class show no benefit over placebo; no controlled evidence exists for Erythranthe kelloggii or any Mimulus species specifically in emotional wellness applications.
Based on the traditional use record and available (very limited) contemporary supplement literature, Kelloggii's monkey-flower has been associated with the following body systems and health areas. In every case the association is traditional in origin, and no clinical evidence base was identified for this specific species:
No peer-reviewed clinical or pharmacological study specifying a dose regimen for Erythranthe kelloggii (syn. Mimulus kelloggii) was identified. The following observations can be made based on available sources:
No species-specific dosage information for Erythranthe kelloggii exists in the peer-reviewed literature, government health databases, pharmacopeial monographs, or other authoritative sources reviewed for this article.
There is little to no scientific research validating the efficacy or safety of Kelloggii's monkey-flower for treating skin abrasions or scratches. No formal toxicological studies, no pharmacovigilance data, no adverse event reports, and no drug-interaction studies specifically related to Erythranthe kelloggii were identified in any of the databases searched, including PubMed, NIH ODS, or NCCIH resources.
For Bach flower remedies as a category (which use highly dilute Mimulus flower preparations), based on the reported adverse events in six controlled trials, BFRs are probably safe. However, this safety determination applies to the heavily diluted, brandy-preserved flower essence preparations and cannot be extrapolated to concentrated botanical extracts, teas, or poultices made from the plant.
Erythranthe kelloggii does not appear in any WHO monograph, ESCOP monograph, German Commission E assessment, European Pharmacopoeia entry, USP dietary supplement monograph, or EFSA opinion identified in the searches conducted for this article. It has not been reviewed by the NIH Office of Dietary Supplements (ODS) or the National Center for Complementary and Integrative Health (NCCIH).
Because the plant is a wild annual herb of disturbed substrates including rockslides and scree in a narrow geographic range, the species is native to the mountains and foothills of northern California and southern Oregon, issues of correct species identification, possible adulteration with other Erythranthe or Diplacus species, and the absence of any standardized extraction methodology represent practical considerations for supply-chain integrity.
Specific historical documentation regarding Mimulus kelloggii is limited, and most ethnobotanical records focus on the broader genus. In the absence of species-specific toxicology studies or official regulatory reviews, no safety conclusions can be drawn with confidence.
Kelloggii's monkey-flower (Erythranthe kelloggii, formerly Mimulus kelloggii) is a small annual wildflower of the family Phrymaceae, restricted in its native habitat to northern California and southern Oregon. Its identity as a dietary supplement or "natural ingredient" rests almost entirely on extrapolations from the broader Mimulus genus rather than on any body of research specific to the species itself.
The traditional use record for this particular species is sparse; specific historical documentation regarding Mimulus kelloggii is limited, and most ethnobotanical records focus on the broader genus. Related species β particularly Mimulus guttatus β have a more extensive indigenous use history in California and the Pacific Northwest, including topical wound care, analgesic steambaths, and gastrointestinal preparations.
At the genus level, flavonoids, phenolic acids, and anthocyanins are documented phytochemical constituents, with preliminary in vitro associations to antioxidant activity. No phytochemical analysis, pharmacological study, or clinical trial specific to Erythranthe kelloggii was identified. While some research on related Mimulus species has demonstrated promising biological activities, there are currently no large-scale clinical studies of any kind on this species.
The Bach flower remedy system has historically employed Mimulus (primarily M. guttatus) for anxiety and fear-related states, but systematic review of controlled trials for Bach flower remedies as a class finds no evidence of benefit compared with a placebo intervention for psychological endpoints.
In sum, Kelloggii's monkey-flower is a very poorly studied botanical ingredient. Its characterization in supplement contexts substantially outpaces the available scientific evidence. No verified dosage, confirmed mechanism of action, or demonstrated clinical benefit can be attributed to Erythranthe kelloggii on the basis of the current peer-reviewed literature.
Health conditions that Kelloggii's monkey-flower may help support.
Body systems that Kelloggii's monkey-flower may help support.